

**AstraZeneca****IA7 Rec'd PCT/PTO 08 MAR 2006****PCT.****IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE**

Application No.: 10/552425	Applicant: MORTLOCK, Andrew
371 Filing Date: Not yet assigned	Attorney Docket No.: 101015-1US
Examiner: Not Yet Assigned	Group Art Unit : Not yet Assigned
Customer No.: 44992	Confirmation No.: 6673
Title: QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 1, 2006

Signature
Janine Proctor

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

Page 1 of 2

AstraZeneca
Global Intellectual Property
SE-151 85 Södertälje
Sweden

Tel +46 8 553 260 00
Fax +46 8 553 286 20
www.astrazeneca.com

Reg Office AstraZeneca AB (publ)
SE-151 85 Södertälje Sweden
Reg No 550011-7482
VAT No SE55011748201


REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:
before the mailing of the **first Office Action** on the merits, and therefore no fee is believe due.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101015-1P US.

Respectfully submitted,



Name: Lucy Padgett
Dated: March 1, 2006
Phone No.: +1 781-839-4182
Reg No.: L0074

Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451

Enclosures: Form SB08A (1 sheet – 12 documents)
Form SB08B (1 sheet – 2 documents)
Return Receipt Postcard



ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

PTO/SB/06A (06-03)

Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 1 of 2

Complete if Known

Application Number	10/552425
Filing Date	Not yet Assigned
First Named Inventor	MORTLOCK, Andrew
Art Unit	2024 1624
Examiner Name	NOT ASSIGNED T. Truong
Attorney Docket No.	101015-1P US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AA	WO 01/21597	03-29-01	AstraZeneca AB		<input type="checkbox"/>
	AB	WO 02/00649	01-03-02	AstraZeneca AB		<input type="checkbox"/>
	AC	WO 03/55491	07-10-03	AstraZeneca AB		<input type="checkbox"/>
	AD	WO 04/58782	07-15-04	AstraZeneca AB		<input type="checkbox"/>
	AE	WO 04/58752	07-15-04	AstraZeneca AB		<input type="checkbox"/>
	AF	WO 04/58781	07-15-04	AstraZeneca AB		<input type="checkbox"/>
	AG	WO 01/21597	03-29-01	AstraZeneca AB		<input type="checkbox"/>
	AH	WO 02/00649	01-03-02	AstraZeneca AB		<input type="checkbox"/>
	AI	WO 03/55491	07-10-03	AstraZeneca AB		<input type="checkbox"/>
	AJ	WO 04/58781	07-15-04	AstraZeneca AB		<input type="checkbox"/>
	AK	WO 04/58752	07-15-04	AstraZeneca AB		<input type="checkbox"/>
	AL	WO 95/15758	06-15-95	Rhonepoulenc Rorer Pharmaceuticals Inc.		<input type="checkbox"/>
	AM	WO04/58782	07-15-04	AstraZeneca AB		<input type="checkbox"/>
Examiner Signature	/Tamthom Truong/			Date Considered	06/05/2008	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/552425
Filing Date	Not yet Assigned
First Named Inventor	MORTLOCK, Andrew
Art Unit	2624 1624
Examiner Name	DEBORAH T. TRUONG T. Truong

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/T.N./	AA	M.D. ANDERSON, The Aurora Kinases: Role in cell transformation and tumorigenesis, Cancer and Metastasis Reviews Vol. 22, 2003, page 451-64, Baylor College of Medicine, Texas	<input type="checkbox"/>
/T.N./	AB	MAHADEVAN, DARUKA, Structure-Based Design of Novel Anti-Cancer Agents Targeting Aurora Kinases, Current Medicinal Chemistry, Anti Cancer Agents Vol. 3, 2003, pages 25-34, Bentham Science Publishers Ltd.	<input type="checkbox"/>
Examiner Signature	/Tamthom Truong/		06/05/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.